Wallbox Receives NYSE Approval for Delisting Compliance Plan, Secures 18-Month Cure Period
WBX has more than doubled off its 52-week low of $2.3 on elevated volume (5.5× avg).
Summary
Wallbox N.V. announced that the NYSE has accepted its plan to regain compliance with listing standards, granting an 18-month cure period to meet market capitalization or stockholders' equity requirements.
Key Events · Corporate Governance and Compliance · WBX
-
NYSE Compliance Plan Accepted
The New York Stock Exchange (NYSE) has accepted Wallbox's plan to regain compliance with its continued listing standards.
-
18-Month Cure Period Granted
Wallbox has been granted an 18-month period, starting from February 12, 2026, to achieve compliance with NYSE listing requirements.
-
Compliance Targets Set
The company must achieve stockholders' equity of at least $50 million or an average global market capitalization of $50 million over a consecutive 30 trading-day period.
-
Continued Listing During Cure Period
Wallbox's Class A ordinary shares will continue to be listed and traded on the NYSE during the 18-month cure period, subject to ongoing review.
Analysis · WBX · Manufacturing
The NYSE's acceptance of Wallbox's compliance plan is a critical development, removing the immediate threat of delisting that arose from the non-compliance notice issued in February. This grants the company an 18-month window to improve its financial metrics, specifically its market capitalization or stockholders' equity, to meet NYSE standards. This positive step follows a period of significant financial restructuring and a 'going concern' warning, providing a clearer path forward for the company's continued public listing.
At the time of this filing, WBX was trading at $5.58 on NYSE in the Manufacturing sector, with a market capitalization of approximately $100.9M. The 52-week trading range was $2.30 to $7.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.